Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan.
The most common subtype of T-/natural killer (NK) cell lymphoma in Japan is adult T-cell leukemia-lymphoma (ATL), which is associated with the human T-cell lymphotropic virus type I (HTLV-1). The investigators in Japan have conducted several clinical trials on multi-agent chemotherapy and stem cell transplantation for patients with ATL. They have also initiated several new clinical trials with a number of agents: an anti-CCR4 antibody, KW-0761; forodesine, a purine nucleoside phosphorylase inhibitor; and lenalidomide, an immunomodulatory agent. Clinical trials with pralatrexate, a folate analog, and denileukin diftitox, an immunoconjugate, are under discussion for patients with ATL and peripheral T-cell lymphoma (PTCL).
Tobinai
Kensei
K
National Cancer Center Hospital, Tokyo, Japan. ktobinai@ncc.go.jp
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D015507:Drugs, Investigational / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007564:Japan; D000077269:Lenalidomide; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery; D015337:Multicenter Studies as Topic; D011684:Purine Nucleosides / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015507:Drugs, Investigational; D007155:Immunologic Factors; D011684:Purine Nucleosides; D011744:Pyrimidinones; C113101:forodesine; D013792:Thalidomide; D000077269:Lenalidomide; C549035:mogamulizumab